<DOC>
	<DOCNO>NCT02300649</DOCNO>
	<brief_summary>Dexmedetomidine selective alpha-2 adrenergic agonist consider adjuvant propofol inhalational anesthetic . Dexmedetomidine mediate cardiovascular effect activation receptor central peripheral nervous system . The classic cardiovascular response dexmedetomidine biphasic initial short-term increase blood pressure follow long-lasting decrease BP HR . There several report hemodynamic change dexmedetomidine , evaluation direct effect cardiac function . The purpose study evaluate effect dexmedetomidine anesthetic adjuvant cardiac function use transesophageal echocardiography .</brief_summary>
	<brief_title>Transesophageal Echocardiographic Evaluation Effect Dexmedetomidine Infusion Adjuvant General Anesthesia Cardiac Function</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . Above 20 year age . 2 . American Society Anesthesiologists ( ASA ) Physical Status I , II , III . 3. general anesthesia 1. severe functional liver kidney disease 2. diagnose HF ( NYHA class &gt; 3 ) 3. arrhythmia receive treatment antiarrythmic drug . 4. severe bradycardia ( HR &lt; 45 bpm ) AV block 5. pathologic esophageal lesion ( esophageal stricture varix ) 6. pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>